Conference Coverage

Original research expands at AACE 2018


 

FROM AACE 2018

A growing focus of the annual meeting of the American Association of Clinical Endocrinologists is on clinical research.

This year’s meeting, in Boston May 16-20, has brought in a record number of accepted abstracts – 1,126 – in all areas of endocrinology. The lion’s share focuses on diabetes, thyroid disease, and bone disease. Most will be presented in Poster Viewing and Judging sessions at 10:00 a.m on Thursday for young investigators and during a poster viewing and wine and cheese reception from 4:30 p.m. to 6:30 p.m. on Friday for senior investigators.

mjbs2/Thinkstock

Boston

The three winning abstracts of the poster competition among young investigators will be presented on Thursday from 12:00 p.m. to 12:45 p.m., and those for senior investigators will be discussed at the same time on Friday. Oral presentations of the overall winners can be heard at a late-breaking abstracts session on Saturday from 10:00 a.m. to 11:00 a.m. All presentations will be in the exhibit hall.

Of note, the mother lode of clinical trials, retrospective analyses, and registry studies will be shown at the senior investigator competition on Friday evening.

That viewing session will include two post hoc analyses of data from the global SUSTAIN trial program in the investigational GLP-1 receptor agonist semaglutide. The first, Abstract 245, examines whether reductions in body weight and HbA1c differed between elderly and younger patients in SUSTAIN 7. The second, Abstract 298, is an analysis of SUSTAIN 1-5 and 7, looking at semaglutide’s effectiveness across racial and ethnic subgroups.

Another large trial, CANVAS, will be represented in two abstracts in this Friday session. In CANVAS, canagliflozin for primary prevention didn’t significantly reduce cardiovascular events in patients with at-risk type 2 diabetes, but it did so convincingly in a secondary prevention population. Outcomes by age group will be presented in Abstract 233, while those by changes in HbA1c and use of antihyperglycemic drugs will be presented in Abstract 262.

Other studies of interest in this viewing session include but are not limited to a comparison of the effects of hypnosis and certified diabetes educators on weight loss and changes in HbA1c levels (Abstract 602) and an investigation into whether the anabolic agent teriparatide can aid in foot bone remodeling in patients with Charcot neuroarthropathy (Abstract 225).

Next Article:

   Comments ()

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge